Curated News
By: NewsRamp Editorial Staff
October 06, 2026
Telomir Pharma Raises $5.6M for TNBC Trial
TLDR
- Telomir Pharmaceuticals raised $5.6 million in a PIPE with no warrants, giving investors a discounted entry to its FDA-cleared TNBC trial.
- Telomir Pharmaceuticals issued 4,843,300 shares at $1.16 per share in a PIPE financing, with proceeds funding the Phase 1/2 trial of Telomir-Zn.
- Telomir Pharmaceuticals secured $5.6 million to advance Telomir-Zn, a potential new therapy for patients with advanced triple-negative breast cancer.
- Telomir Pharmaceuticals raised $5.6 million, including $1 million from John Paul DeJoria, to support its first-in-human trial for Telomir-Zn in TNBC.
Impact - Why it Matters
This financing provides Telomir Pharmaceuticals with critical capital to advance Telomir-Zn into first-in-human trials for triple-negative breast cancer, a particularly aggressive and hard-to-treat disease with limited therapeutic options. The FDA's IND clearance and the backing from existing investors, including John Paul DeJoria, underscore confidence in the company's novel approach targeting epigenetic and metabolic pathways. If successful, Telomir-Zn could offer a new treatment paradigm for TNBC patients and potentially other cancers, making this a significant development in oncology. For investors, the non-dilutive structure of the PIPE (no warrants) may be seen as a positive signal, though clinical-stage biotech remains high-risk.
Summary
Telomir Pharmaceuticals (NASDAQ: TELO) has secured an approximately $5.6 million private investment in public equity (PIPE) financing, issuing 4,843,300 common shares at $1.16 per share—a 5% discount to the 10-day volume-weighted average price. Notably, the financing includes an additional $1 million from existing significant shareholder John Paul DeJoria and comes without investor warrants, convertible securities, or variable-price/reset features, signaling strong confidence in the company’s direction.
The net proceeds will primarily fund clinical development of Telomir-Zn, including a Phase 1/2 trial in advanced or metastatic triple-negative breast cancer (TNBC), as well as working capital and general corporate purposes. The FDA has cleared the Investigational New Drug (IND) application for Telomir-Zn, allowing the company to proceed with its first-in-human study. Telomir Pharmaceuticals is a clinical-stage biotechnology company focused on small-molecule therapeutics targeting epigenetic and metabolic pathways in cancer. Its lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation.
InvestorWire (IW), a specialized communications platform, syndicated the announcement. IW is part of the Dynamic Brand Portfolio @ IBN, offering wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more details, visit the full press release at https://ibn.fm/0KMpl.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Telomir Pharma Raises $5.6M for TNBC Trial
